856562-95-3

Usage

Uses

Used in Pharmaceutical Industry:
(R)-1-(3-Methoxyphenyl)propan-1-amine hydrochloride is used as a medicinal agent for the treatment of certain medical conditions such as attention deficit hyperactivity disorder (ADHD) and narcolepsy. Its stimulant properties help improve focus, attention, and reduce fatigue in patients with these conditions.
Used in Recreational Context:
Despite its medicinal uses, (R)-1-(3-Methoxyphenyl)propan-1-amine hydrochloride is also used recreationally for its stimulating effects, which can lead to increased alertness and a sense of euphoria. However, it is important to note that the recreational use of this substance is illegal in many jurisdictions and can result in serious health consequences due to its high potential for addiction and abuse.
It is crucial to emphasize that while (R)-1-(3-Methoxyphenyl)propan-1-amine hydrochloride has legitimate medical applications, its non-medical use and the risks associated with addiction and health issues make it a substance that requires strict regulation and control.

Upstream product

• 591-31-1 3-methoxy-benzaldehyde 
• 1015198-48-7 (R)-N-(3-methoxybenzylidene)-2-methylpropane-2-sulfinamide 

Relevant academic research and scientific papers

Synthesis and Structure-Activity Relationships of N-(4-Benzamidino)-Oxazolidinones: Potent and Selective Inhibitors of Kallikrein-Related Peptidase 6

Kallikrein-related peptidase 6 (KLK6) is a secreted serine protease that belongs to the family of tissue kallikreins. Aberrant expression of KLK6 has been found in different cancers and neurodegenerative diseases, and KLK6 is currently studied as a potential target in these pathologies. We report a novel series of KLK6 inhibitors discovered in a high-throughput screen within the European Lead Factory program. Structure-guided design based on docking studies enabled rapid progression of a hit cluster to inhibitors with improved potency, selectivity and pharmacokinetic properties. In particular, inhibitors 32 ((5R)-3-(4-carbamimidoylphenyl)-N-((S)-1-(naphthalen-1-yl)propyl)-2-oxooxazolidine-5-carboxamide) and 34 ((5R)-3-(6-carbamimidoylpyridin-3-yl)-N-((1S)-1-(naphthalen-1-yl)propyl)-2-oxooxazolidine-5-carboxamide) have single-digit nanomolar potency against KLK6, with over 25-fold and 100-fold selectivities against the closely related enzyme trypsin, respectively. The most potent compound, 32, effectively reduces KLK6-dependent invasion of HCT116 cells. The high potency in combination with good solubility and low clearance of 32 make it a good chemical probe for KLK6 target validation in vitro and potentially in vivo.